You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,320,961

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,320,961

Title:	Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
Abstract:	The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
Inventor(s):	Kempf; Dale J. (Libertyville, IL), Bertz; Richard J. (Kenosha, WI), Waring; Jeffrey F. (Franklin, WI)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	10/802,829
Patent Claims:	1. A method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir, wherein said elevated serum concentration of the UGT1A1 substrate is not caused by administration of atazanavir. 2. The method of claim 1 wherein the disease or disorder is unconjugated hyperbilirubinemia. 3. The method of claim 1 wherein the UGT1A1 substrate is bilirubin. 4. The method of claim 1 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily. 5. A method for treating unconjugated hyperbilirubinemia comprising the step of administering an effective amount of ritonavir to a subject in need thereof, wherein said unconjugated hyperbilirubinemia is not caused by administration of atazanavir. 6. The method of claim 5 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily. 7. A method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering ritonavir in an effective amount to a subject in need thereof, wherein said elevated serum concentration of the UGT 1 A1 substrate is not caused by administration of atazanavir. 8. The method of claim 7 wherein the effective amount of ritonavir is in a range of about 25 mg to about 1200 mg. 9. The method of claim 7, wherein said elevated serum concentration of the UGT1A1 substrate is a result of administration of an active pharmaceutical ingredient to the subject, and wherein the active pharmaceutical ingredient is selected from the group consisting of indinavir, amphotericin B/cholesteryl sulfate complex, testosterone, interferon beta-1b, bicalutamide, ciprofloxacin, oxaliplatin, floxuridine, gemcitabine hydrochloride, sargramostim, gemtuzumab ozogamicin, vinorelbine tartrate, carboplatin, peginterferon alfa-2B, tacrolimus, aldesleukin, dalfopristin/quinupristin, didanosine and capecitabine. 10. The method of claim 9 wherein the active pharmaceutical ingredient is indinavir. 11. The method of claim 7 wherein the disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate is unconjugated hyperbilirubinemia.

Details for Patent 7,320,961

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992	⤷ Try a Trial	2023-03-24
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991	⤷ Try a Trial	2023-03-24
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991	⤷ Try a Trial	2023-03-24
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993	⤷ Try a Trial	2023-03-24
Merck Sharp & Dohme Corp.	PEGINTRON	peginterferon alfa-2b	Injection	103949	01/19/2001	⤷ Try a Trial	2023-03-24
Merck Sharp & Dohme Corp.	SYLATRON	peginterferon alfa-2b	For Injection	103949	03/29/2011	⤷ Try a Trial	2023-03-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.